Followers | 2540 |
Posts | 250759 |
Boards Moderated | 35 |
Alias Born | 05/06/2014 |
Saturday, December 12, 2015 2:45:14 PM
Source: GlobeNewswire Inc.
Dyadic International, Inc. (OTCQX:DYAI) (“Dyadic”) announced that at the special meeting of Dyadic shareholders held today, Dyadic’s shareholders voted to approve the sale of substantially all of the enzyme and technology assets, including the C1 platform of Dyadic, Dyadic International (USA), Inc. (“Dyadic USA”) and Dyadic Nederland B.V. to Danisco US Inc., a wholly-owned subsidiary of E. I. du Pont de Nemours and Company, (“Danisco”) and its affiliate (the “Transaction”) pursuant to the asset purchase and sale agreement, dated as of November 9, 2015, by and among Danisco, Dyadic USA and Dyadic (the “Transaction Agreement”).
The affirmative vote of the holders of at least a majority of the shares of Dyadic common stock outstanding and entitled to vote thereon at the special meeting was required to approve the Transaction pursuant to the Transaction Agreement. According to the final tally of shares voted, approximately 77% of the outstanding shares of Dyadic’s common stock as of the close of business on the record date of November 13, 2015 were voted to approve the Transaction pursuant to the Transaction Agreement. A quorum of approximately 78% of Dyadic’s total outstanding shares of common stock as of the November 13, 2015 record date voted at the special meeting.
The proposed Transaction was announced on November 9, 2015 and is expected to close on December 31, 2015.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at www.dyadic.com.
Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic, as well as additional information related to its professional liability lawsuit, in the company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. Factors that could cause results to differ materially include, but are not limited to: (1) the likelihood that the transaction is consummated on a timely basis or at all, including whether the conditions required to complete the transaction will be met, (2) general economic conditions, including the recent conditions in the global markets; (3) Dyadic’s ability to retain and attract employees during the pendency of the transaction and following the closing of the transaction; (4) competitive pressures and reliance on key customers and collaborators; (5) Dyadic’s research and development efforts, (6) the outcome of the current litigation by Dyadic against its former counsel, (7) Dyadic’s ability to obtain additional debt or equity financing sources and (8) other factors discussed in Dyadic’s Proxy Statement and other publicly available filings, including information set forth under the caption “Risk Factors” in our December 31, 2014 Annual Report filed with OTC Markets on March 27, 2015. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us.
Contact:
Dyadic International, Inc.
Mark A. Emalfarb
Chief Executive Officer
Phone: 561-743-8333
Primary Logo
Recent DYAI News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:17:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:15:54 PM
- Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 07/30/2024 08:00:00 PM
- Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership • GlobeNewswire Inc. • 06/28/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 01:26:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:31:42 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/06/2024 09:36:45 PM
- Dyadic to Attend Industry Events in June • GlobeNewswire Inc. • 05/30/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 07:42:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:47:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:47:30 PM
- Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress • GlobeNewswire Inc. • 05/14/2024 08:00:00 PM
- Dyadic to Attend Industry and Investor Events in May • GlobeNewswire Inc. • 05/08/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/08/2024 04:15:21 AM
- Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:30:00 PM
- Dyadic Reports 2023 Full Year Results and Recent Company Progress • GlobeNewswire Inc. • 03/28/2024 08:00:00 PM
- Dyadic Announces Change in Board and Management Leadership Roles • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- Dyadic to Attend Industry Events in April • GlobeNewswire Inc. • 03/27/2024 12:30:00 PM
- Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024 • GlobeNewswire Inc. • 03/14/2024 08:30:00 PM
- CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization • GlobeNewswire Inc. • 03/11/2024 01:57:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:45:28 PM
- Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization • GlobeNewswire Inc. • 03/11/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM